2017 | 03 | 30

Vironova is building a state of the art electron microscopy (EM) facility to meet increasing demand

Vironova has established a growing number of global customers in the highly-regulated and quality demanding pharmaceutical industry, who focus on drug/gene delivery and vaccine development. Currently 7 of the 10 largest biopharmaceutical companies are clients to Vironova.

The new EM facility with a BSLII laboratory for sample preparation will greatly increase current capacity and meet the increasing demand for nanoparticle characterization services that the company provides. These are performed using TEM and the proprietary image analysis software VAS (Vironova Analyzer Software) in accordance with GMP, which is essential for applications in pharmaceutical development. Several Microscopists are being recruited for the new lab, which will be finalized during this year.

News and events

Read about the latest news and events at Vironova.

  • All news
  • Inside Vironova
  • Open positions
  • Events and publications
VIEW MORE
VIEW MORE
VIEW MORE
VIEW MORE

On demand webinar

  • Title: Unmatched Viral Particle Analysis in Vaccine and Gene Therapy Development
  • Speaker: Josefina Nilsson, head of EM services & Martin Ryner, Strategic development manager
  • Watch webinar

Upcoming events 2017

Cell & Gene Therapy Europe 2017
6-7 December, Amsterdam
Booth 24

Vironova on MyNewsDesk

Follow us on MyNewsDesk and get the latest info on investor relations, events and company news.
Click here to get to our MyNewsDesk-page.

Press contact
For press enquiries, please contact
info@vironova.com

IR contact
Mohammed Homman
ceo@vironova.com